



石四藥集團有限公司

SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)
(Stock Code : 2005)

SSY announces 2024 annual results
Net profit HK\$1,061 million; Final dividend HK\$0.095/share
Business environment remained complex;
Focus on innovation with improvements in quality & efficiency

Result summary:

- Revenue HK\$5,773 million, representing a decrease of 10.7% (in terms of RMB, drop of 9.6%);
- Net profit HK\$1,061 million, representing a decrease of 19.5%;
- The Board resolved to pay final dividend of HK\$0.095 /share, whole year dividend HK\$0.175 /share, representing an increase of 2.9%

(28 March 2025 – Hong Kong) **SSY Group Limited** (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the annual results of the Company for the year ended 31 December 2024 (“2024” or “the year”).

In 2024, the Group achieved a revenue of approximately Renminbi (“RMB”) 5,266 million, representing a decrease of approximately 9.6% as compared to last year. In terms of Hong Kong dollars, the Group’s sales revenue was approximately HK\$5,773 million in the year, representing a decrease of approximately 10.7% as compared to last year. The Group achieved a net profit of approximately HK\$1,061 million, representing a decrease of approximately 19.5% as compared to last year. The internal and external business environment remained severe and complex. Faced with multiple challenges and impacts such as sluggish economic recovery, intensified trade protectionism, and tightening medical insurance policies, the Group overcame difficulties and implemented comprehensive measures, facing difficulties and challenges with a positive attitude and proactive actions. By adopting an accelerated stance, we focused on innovation, optimized production and sales mix, expanded market coverage in a targeted manner, promoted the dominant and key preparations products, and expanded business scope as well as improved quality and efficiency of commodity bulk pharmaceuticals and medical materials. The Group’s overall business maintained a trend of stable development.

The Board of directors resolved to pay a final dividend of HK\$0.095 per share for year 2024, together with interim dividend of HK\$ 0.08 per share, total dividend for the year were HK\$0.175 per share, representing an increase of approximately 2.9% as compared to last year. The total amount to be paid is approximately HK\$518 million.

In 2024, revenue of intravenous infusion solutions achieved HK\$3,735 million, representing a decrease of 7.6% compared to last year; sales volume reached 2,036 million bottles (bags),

representing an increase of 6.7% compared to last year. This was mainly due to sluggish demand and price decline in the basic infusion existing market as affected by a combination of policy and market factors, which resulted in weaker-than-expected growth. During the year, the aggregated sales volume of ampoule injection products reached 313 million, representing an increase of 1.3% as compared to last year. The Group experienced further growth in the production and sales scale of its oral preparations business segment. Through proactively adjusting market layout, the Group strengthened the business cooperation with the top 100 chain pharmacies and pushed forward the commercial chain to speed up the development of end market. During the year, revenue reached approximately HK\$502 million, representing an increase of approximately 4.9% as compared to last year. The overall business of the bulk pharmaceuticals segment was affected by the international market and pricing factors. External revenue of bulk pharmaceuticals reaching approximately HK\$785 million, representing a decrease of 11.7% as compared to last year. Jiangsu Best New Medical Material continued to strengthen the complementarity of the industrial chain, the external sales reached HK\$188 million, representing a growth of 16.4%.

The Group has continuously intensified the development of new products such as specialized generic drugs, drugs in shortage, orphan drugs, innovative drugs, and bulk pharmaceuticals, maintaining a leading position in the industry in terms of the number of submissions and approvals. The Group focuses on market demand and strives to strategically deploy in the fields of antiviral, antibacterial, neurological system, cardiovascular, digestive, anesthesia and analgesia, and anti-tumor products. During the year, 112 production approvals and 7 clinical approvals were obtained. 131 projects for product approvals were submitted, of which 76 were new liquid and solid preparations as well as 27 were bulk pharmaceuticals. Positive progress has been made in the research of innovative drugs. The self-developed Type I new drug SYN045 has received approval for clinical trials and is currently undergoing Phase I clinical trials. Type 1 chemical innovative drug ADN-9 for anti-liver fibrosis has completed preclinical research, aiming to submit the clinical trial application in 2025. For the development of solid preparations, the Group has established a technology platform for slow-release and osmotic pumps, leading to the development layout of several preparations with high technical requirements and high industrialization thresholds. The Group is actively developing various liposome projects in the areas of the research of several complex preparations. These endeavors highlighted the Group's growing technological influence in the field of complex preparations.

The Group coordinated the progress of industrial infrastructure construction projects, including plastic bottle injection production line, ready-made double-chamber bags for large-volume injection production line, and sterile preparations of hormones production line. Additionally, the Group has made progress in the construction of new and ongoing projects, including Pharmaceutical Integration and Innovation Development Demonstration Project, and high-end bulk pharmaceuticals construction project. All projects have been completed except for Pharmaceutical Integration and Innovation Development Demonstration Project, which is progressing in an orderly manner as planned. Among them, the construction project of the plastic bottle injection production line passed the GMP compliance inspection in November 2024 and has been formally put into production.

Looking ahead to 2025, adverse effects brought by changes in external environment have deepened, and pharmaceutical industry both domestically and internationally still faces numerous difficulties and challenges. Facing the new situation and changes in pharmaceutical industry, the Group will confront difficulties with confidence, adhere to innovation, and we will continuously

promote the deep integration of the innovation chain, supply chain and value chain, facilitate the domestic-international dual circulation, and achieve the goals of solid expectations and steady growth. To establish and improve operational mechanisms that better adapt to current policies and market conditions. Focusing on market, driving the enhancement of R&D and production efficiency from the marketing end, further reducing costs, solidifying expectations, stimulating vitality and continuously improving operational quality of the Group. On the preparations business, the Group will focus on quality improvement and efficiency enhancement. The Group adheres to the balanced development of traditional dominant products and new product markets, further promotes the optimization and upgrading of the production and sales mix, and strives to transform innovation advantages into market advantages and development advantages. On the bulk pharmaceuticals business, the Group will continuously improve the product mix, accelerate the implementation and transformation of new high-value-added specialized products, and pursue integrated development in high-end, intelligent and green to continuously empower the resilience and vitality of bulk pharmaceuticals development. The Group will firmly adhere to the strategy of “combination of generic and innovative drugs”, closely integrating the development of “bulk pharmaceuticals + preparations”. We aim to continuously optimize the innovation ecosystem, and create new advantages in R&D approval and application efficiency. The Group will systematically advance the construction progress of new and ongoing projects and continuously accumulate momentum and energy for the sustainable development of the Group.

Mr. Qu Jiguang, Chairman and CEO of SSY said, “The Group will leverage its own strengths to actively seek opportunities for mergers and acquisitions as well as investments in the pharmaceutical industry, with the aim of enhancing and strengthening the supply chain, creating new growth poles, and reinforcing the Group’s position in the product and capital markets to increase the return on investment. Despite the tough road ahead, we are foreseeing positive results and bright prospects with a higher courage to overcome difficulties. In this new year, the Group will unite as one, stick to new targets, and apply self-pressure to seek breakthroughs and rooms through innovation and transformation. By seeking innovation amid change and advancing with breakthroughs, the Group will rise to the challenges with a strong confidence, and strive to implement and achieve the key task and targets for year 2025. We firmly believe that with our advantages in scale, quality, management and branding built up in the industry over the years, and with our continuous innovative momentum, we will bring satisfactory returns to our investors with more solid development results.”

– End –

About SSY Group Limited

SSY Group Limited is one of the leading pharmaceutical manufacturers in China with nearly 7 decades of operation history and a well-established brand name. The Group went public on the Hong Kong Stock Exchange in December 2005 with stock code 2005. The Group is principally engaged in the research, development, manufacturing and selling of pharmaceutical products, including finished medicines of mainly intravenous infusion solution and ampoule injection to hospitals and distributors, bulk pharmaceuticals and medical materials. The manufacturing plants of the Group locates in Hebei Province and Jiangsu Province in China, and its pharmaceutical products has leading position in the high-end hospital market in China.